Nephrodite, Inc. is developing a combined implantable and wearable renal replacement dialysis device that represents a change in the way end-stage kidney disease and dialysis care is delivered.
Nephrodite is developing Holly, a combined implantable and wearable device that represents a change in the way End-Stage Renal Disease and dialysis care is delivered. Development of Holly was inspired from a patient cared for by our physician Founders. Holly is a true kidney replacement solution. One of the greatest attributes of Holly is returning autonomy to patients. Our device will offer mobility and independence to patients enjoying freedom to do as they choose with their time. With continuous clearance of toxins and water exchange, Holly eliminates the need for ‘in-center’ hemodialysis, reduces the immobility required for home and peritoneal dialysis and improves health over standard intermittent dialysis. In addition, there would be no complications associated with arm grafts and fistulas plus a marked reduction in needle sticks. The company has cleared critical development milestones, recently completing acute animal studies showing device efficacy and function.
After being selected for the program from thousands of applicant companies last Fall 2021, Nephrodite is among a select group of ventures in the latest cohort to graduate. “We have absolutely grown, matured and emerged as a more efficient and functional company than when we started 8 months prior. The CDL network provided necessary, unfiltered and critical guidance throughout the program. I can definitively state that we our milestones and inflection points are aligned to a well-crafted roadmap largely due to the mentorship of the CDL network” said Dr. Nikhil Shah, Nephrodite’s CEO & Co-Founder. “Quite frankly, I really did not initially appreciate the sheer talent and depth of expertise that we were given access to. If I had to look for this in the market, it would be at great expense to the company” said Vik Vijayvergiya, Co-Founder of Nephrodite.
After completing CDL, Nephrodite will be completing financing of the Seed Round. With these funds, they plan to submit key regulatory documents, as well as complete several key R&D milestones expanding upon the success that they have already achieved. “Nephrodite, Inc. is really appreciative of the opportunities and mentorship provided by CDL and to be recognized as a CDL graduate company. Our novel implantable dialysis device is being developed to improve quality of life and health outcomes for patients with end-stage renal disease.” said Dr. Hiep Nguyen, Nephrodite’s Co-founder and Chief Science Officer.
About Nephrodite, Inc.
At Nephrodite, we envision a world where dialysis doesn’t mean stopping your life. Our team of scientists, engineers, and clinicians is dedicated to improving the lives of patients with End Stage Renal Disease through the development and commercialization of our fully implantable continuous dialysis device – Holly. Holly is a patent protected device in preclinical development that works while you live life without the need to spend your waking hours immobile, hooked up and tethered to externalized machines.
About the Creative Destruction Lab
The Creative Destruction Lab (CDL) is a seed-stage program for massively scalable, science-based companies. The nine-month program employs an objectives-based mentoring process with the goal of maximizing equity-value creation. The CDL is particularly suited to early-stage companies with links to university research labs.
